MedTrace Logo

Single cEll pRofiling PErsistaNce To ImmuNothErapy

NCT06680739 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-11-08

No results posted yet for this study

Summary

The SERPENTINE trial (ESR 21-21165) is a phase II clinical study aiming to evaluate the efficacy of durvalumab and tremelimumab, alone or in combination, in patients with colorectal or endometrial cancer. The trial targets patients with microsatellite instability-high (MSI-H) tumors and those with microsatellite stable (MSS) tumors.

Colorectal and endometrial cancers present significant challenges due to their heterogeneity and variable responses to treatment. Immunotherapy, particularly checkpoint inhibitors like durvalumab and tremelimumab, has shown promise in some patients, but predicting response remains elusive. The SERPENTINE trial aims to address this gap by investigating the effectiveness of these immunotherapies in a carefully selected patient population.

Conditions

Interventions

DRUG

Durvalumab

Durvalumab 1500 mg IV every 4 weeks

DRUG

Tremelimumab

Tremelimumab 300 mg IV as a single dose

Sponsors & Collaborators

  • Vall d'Hebron Institute of Oncology

    lead OTHER

Principal Investigators

  • Elena Elez, MD PhD · Vall d'Hebron Institute of Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2025-09-01
Completion
2025-12-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06680739 on ClinicalTrials.gov